# Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

> **NCT06207799** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma
- Post-transplant MRD-guided Maintenance Therapy
- Pre-transplant Purging

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Lenalidomide
- **DRUG:** Plerixafor
- **DRUG:** Melphalan
- **DRUG:** Busulfan
- **DRUG:** G-CSF
- **PROCEDURE:** Stem cell transplant

## Key facts

- **NCT ID:** NCT06207799
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06207799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06207799, "Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06207799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*